Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
RNI review: MA.20 10-yr DFS 82% vs 77%, EORTC 22922 72.1% vs 69.1%, no OS gain in either trial alone; breast nodal RT carries a review-only day.
All five sources are narrative reviews, no new trial readouts. Breast carries the day: RNI (MA.20/EORTC 22922 DFS gains, pooled 1-2% 10-yr OS), ALND omission after Z0011/AMAROS, and response-adapted PMRT after NAC (ypN+ no-RT LRR ≥15%). Prostate urethral dose steering and liver SBRT BED ≥100 Gy10 (3-yr LC 93% vs 65%) round out RT technique.
read the full digest →Studies · 281
- SBRT for liver metastases (Seminars in Radiation Oncology review)BED ≥100 Gy10 tied to 3-year LC 93% vs 65% in liver mets; review maps fractionation to OAR distance and liver dose constraints.
- Surgery and radiotherapy for regional nodes in breast cancer10-yr LRR 6.2% ALND vs 5.3% SLNB alone (P = .36) in Z0011 anchors this review of ALND omission and nodal RT field choice.
- Clinical perspective on regional nodal irradiation for breast cancer10-yr DFS 82% vs 77% (MA.20) and 72.1% vs 69.1% (EORTC 22922) with RNI, no OS gain in either trial alone.
- Radiation decisions after neoadjuvant chemotherapy and mastectomyNo randomised post-NAC PMRT data: retrospective MDACC/NSABP series put ypN+ LRR without RT at ≥15%, cT1–T2 ypN0 <10%, supporting response-adapted PMRT.
- Urinary toxicity from prostate radiotherapy: mechanisms, mitigation, managementNarrative review: urethral dose steering (FLAME-derived D0.1 cm³ <105% Rx; SBRT Dmax <107% → est. 7.7% late moderate GU) is the main mitigation lever.
- ISRS Technical Guidelines for SRS: Small Brain Metastases (≤1 cm)≤1 mm end-to-end geometric tolerance, ≤7-day planning MRI, ≤1.5-mm slices, dosimetric accuracy within 5%: the ISRS technical floor for SRS to brain mets ≤1 cm.
- Stereotactic Radiosurgery in the Management of Brain Metastases: Case-Based Radiosurgery Society Practice GuidelineRadiosurgery Society case-based guide: SRS suitable for 1-15 lesions ≤3 cm/≤14 cc, fractionate 2-4 cm lesions, surgery first above 4 cm.
- Natural History of DCIS of the Breast: A Review14–53% of DCIS misdiagnosed as benign progressed to invasive cancer over 10+ yrs; CS+RT recurrence 8.9% vs 22.5% after CS alone.
- APBI-IMRT-Florence Technique Update (IMRT to VMAT)30 Gy/5 consecutive-fraction VMAT PBI in 50 pts: no grade >1 acute or late toxicity at median 4.5y; cosmesis excellent/good 98%.
- Implications of Genetic Testing on RT Decisions: A Guide for Radiation OncologistsASTRO think tank: heterozygous germline variants (BRCA1/2, PALB2, CHEK2, VUS) should not alter indicated RT; deleterious ATM in young pts is the exception.
- ASTRO Clinical Practice Guideline: Radiation Therapy for Brain MetastasesSRS strongly recommended for ECOG 0-2 with up to 4 intact mets, conditional for 5-10; HA-WBRT plus memantine strong when WBRT is used.
- International consensus on target volume delineation for sacral metastases and spinal SBRTKappa 0.73 for GTV and 0.59 for CTV across 9 experts and 10 cases; consensus compartment-based sacral CTV built on a new eight-segment classification.